Investigating the use of nicotine for treating complications of levodopa therapy in Parkinsons disease
- Conditions
- Health Condition 1: G20- Parkinsons disease
- Registration Number
- CTRI/2020/12/029965
- Lead Sponsor
- ational Brain Research Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
non-smoker ( >10 years)
- able to provide informed consent
The subjects may not be eligible to participate if he/she -
-Has any neurological disorder (except PD in the patient group)
-Has a current depressive episode, schizophrenia or bipolar disorder (self-declared and screened with GHQ-12 (Goldberg et al., 1978; Qin et al., 2018))
-Has had any head injury with loss of consciousness
- Has had any seizures in the past
-Has cognitive impairment (Mini Mental Status Examination (MMSE) test score <25)
-Abuses drugs/alcohol
-Is pregnant or nursing
Subjects will not be eligible for MRI scanning if they -
-Have non-MRI compatible metal in the body such as a cardiac pacemaker, brain stimulator, surgical metal, cochlear implants, artificial heart valves or dental implants.
-Are unable to lie flat on the back for the duration of the scan.
-Have uncontrollable head movements.
-Are claustrophobic.
Subjects will not be eligible to undergo TMS if they â??
-Have metal implants in the body such as brain stimulator, surgical metal, cochlear implants, cardiac pacemaker, intracardiac lines, implanted pumps or stimulators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Motor cortical inhibition, Motor cortical plasticityTimepoint: baseline, 4 hours after patch, 1 hour after levodopa medication
- Secondary Outcome Measures
Name Time Method cortical connectivity <br/ ><br>cortical reactivityTimepoint: baseline, 4 hours after patch, 1 hour after levodopa